Ono Pharmaceutical

Ono Pharmaceutical's headquarters in Chūō-ku, Osaka, Japan

Ono Pharmaceutical (Japanese: 小野薬品工業) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka. [1], and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. [2]

Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: 小野市兵衛) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: 小野薬品工業株式会社) in 1948.[3]

Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in Match 2018 were 16 billion Japanese yen.[4]

Opdivo, the cancer drug based on the research of Prof./Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.[5]

See also

References

  1. ↑ Ono Pharmaceutical - Manufacturing
  2. ↑ Ono Pharmaceutical - Research & Development
  3. ↑ Ono Pharmaceutical - History]
  4. ↑ "Bloomberg - Are you a robot? | Company Overview of Ono Pharmaceutical Co., Ltd". bloomberg.com. Retrieved 2018-10-04.
  5. ↑ "Spotlight on New Cancer Immunotherapy: Ono Pharmaceutical's Opdivo". Nippon.com. Retrieved 2018-10-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.